Here are the 10-K annual reports from Alpha Cognition Inc. (ACOG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ACOG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACOG filings page.
Alpha Cognition Inc. is a biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s. It has shifted from pure R&D to commercialization with the U.S. launch of ZUNVEYL, an oral acetylcholinesterase inhibitor for mild-to-moderate Alzheimer’s disease, on March 19, 2025.
The company is targeting the long-term care market, where acetylcholinesterase inhibitors account for a large share of more than 11 million annual U.S. prescriptions. ZUNVEYL’s wholesale acquisition cost is set at $820 per month, and Alpha Cognition is negotiating coverage with major pharmacy benefit managers.
Beyond ZUNVEYL, the pipeline includes a fixed-dose combination of ALPHA‑1062 and memantine for moderate-to-severe Alzheimer’s, a sublingual ALPHA‑1062 formulation for patients with swallowing difficulties, and programs in mild traumatic brain injury. A broad patent estate provides protection into the 2040s across multiple jurisdictions and formulations.